{"transactions":[{"id":694301,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":false,"shares":20491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":20491},"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694300,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":false,"shares":23364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":23364},"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694299,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":false,"shares":27567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":25.28,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":27567},"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694298,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":false,"shares":87373,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.48,"expiration_date":"2031-08-01","underlying":"Common Stock","underlying_shares":87373},"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694297,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":158795,"price":60.2134,"value":9561586.853,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694296,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":true,"shares":20491,"price":22.47,"value":460432.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."}],"balance_after":158795,"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694295,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":true,"shares":23364,"price":14.85,"value":346955.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."}],"balance_after":138304,"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694294,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":true,"shares":27567,"price":25.28,"value":696893.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."}],"balance_after":114940,"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":694293,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T00:18:03.000Z","date":"2026-08-04","kind":"exercise","planned":true,"acquired":true,"shares":87373,"price":2.48,"value":216685.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025."}],"balance_after":87373,"source":{"system":"sec-edgar","filing":"0001865125-26-000004","document":"form4-08072026_120853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000004/form4-08072026_120853.xml","form_type":"4"}},{"id":901255,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T00:56:59.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":17126,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date."}],"balance_after":17126,"derivative":{"exercise_price":27.16,"expiration_date":"2036-02-12","underlying":"Common Stock","underlying_shares":17126},"source":{"system":"sec-edgar","filing":"0001865125-26-000001","document":"form4-02182026_120255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000186512526000001/form4-02182026_120255.xml","form_type":"4"}},{"id":1276751,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-10T22:35:32.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":20491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":20491,"derivative":{"exercise_price":22.47,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":20491},"source":{"system":"sec-edgar","filing":"0001415889-25-003518","document":"form4-02102025_100228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000141588925003518/form4-02102025_100228.xml","form_type":"4"}},{"id":1634205,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-21T00:27:39.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":23364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant."}],"balance_after":23364,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":23364},"source":{"system":"sec-edgar","filing":"0001415889-24-004486","document":"form4a-02212024_120231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000141588924004486/form4a-02212024_120231.xml","form_type":"4/A","original_submission_date":"2024-02-15"}},{"id":1641217,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T01:48:40.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":16835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date."}],"balance_after":16835,"derivative":{"exercise_price":14.85,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":16835},"source":{"system":"sec-edgar","filing":"0001415889-24-004014","document":"form4-02162024_010234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000141588924004014/form4-02162024_010234.xml","form_type":"4"}},{"id":1923876,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T00:17:55.000Z","date":"2023-02-23","kind":"grant","planned":false,"acquired":true,"shares":27567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":27567,"derivative":{"exercise_price":25.28,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":27567},"source":{"system":"sec-edgar","filing":"0001209191-23-023664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000120919123023664/doc4.xml","form_type":"4"}},{"id":1990627,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":25897,"kind":"person","name":"Derynck Mika K","position":1,"cik":"0001865125","reported_name":"Derynck Mika K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-28T02:43:42.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":87373,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the \"Merger Agreement\"), by and among Imara Inc. (\"Imara\"), Enliven Therapeutics, Inc., (\"Enliven\") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the \"Merger Sub\"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3))"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option are subject to an early exercise provision and vest in 48 equal monthly installments beginning on September 2, 2021."}],"balance_after":87373,"derivative":{"exercise_price":2.48,"expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":87373},"source":{"system":"sec-edgar","filing":"0001209191-23-013500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865125/000120919123013500/doc4.xml","form_type":"4"}}]}